Arcus Biosciences impressed analysts after updated kidney cancer drug data that strengthened investor confidence in casdatifan, an investigational therapy in late-stage testing. At an R&D day, the company presented follow-up results that suggested a “step-up in potency” compared with Merck’s Welireg, based on outcomes across earlier-line settings. In parallel, TriGemX Bio announced a SPAC deal that would take the company public through a merger with a blank-check vehicle, providing $246 million in cash including $160 million from institutional investors. The move supports continued late-stage development momentum, including elismetrep for acute migraines. Together, the two updates highlight how investors are positioning for next-generation kidney cancer and how SPAC capital continues to be used to accelerate public-market entry for clinical-stage biotech.